Abstract
AbstractChronic lung infections are among the most diffused human infections, being often associated with multidrug-resistant bacteria. In this framework, the European project “Light4Lungs” aims at synthesizing and testing an inhalable light source to control lung infections by antimicrobial photoinactivation (aPDI), addressing endogenous photosensitizers only (porphyrins) in the representative case of S. aureus and P. aeruginosa. In the search for the best emission characteristics for the aerosolized light source, this work defines and calculates the photo-killing action spectrum for lung aPDI in the exemplary case of cystic fibrosis. This was obtained by applying a semi-theoretical modelling with Monte Carlo simulations, according to previously published methodology related to stomach infections and applied to the infected trachea, bronchi, bronchioles and alveoli. In each of these regions, the two low and high oxygen concentration cases were considered to account for the variability of in vivo conditions, together with the presence of endogenous porphyrins and other relevant absorbers/diffusers inside the illuminated biofilm/mucous layer. Furthermore, an a priori method to obtain the “best illumination wavelengths” was defined, starting from maximizing porphyrin and light absorption at any depth. The obtained action spectrum is peaked at 394 nm and mostly follows porphyrin extinction coefficient behavior. This is confirmed by the results from the best illumination wavelengths, which reinforces the robustness of our approach. These results can offer important indications for the synthesis of the aerosolized light source and definition of its most effective emission spectrum, suggesting a flexible platform to be considered in further applications.
Funder
H2020 Future and Emerging Technologies
Università degli Studi di Firenze
Publisher
Springer Science and Business Media LLC
Subject
Physical and Theoretical Chemistry
Reference47 articles.
1. Kidd, T. J., et al. (2018). Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 17, 696–704. https://doi.org/10.1016/j.jcf.2018.08.014
2. Nikolova, P., et al. (2013). Antibiotic resistance in ambulatory patients with chronic obstructive pulmonary disease-clinical signs. European Respiratory Journal, 42, 2733.
3. Johnson, D. C. (2011). Airway mucus function and dysfunction. New England Journal of Medicine, 364, 978. https://doi.org/10.1056/NEJMc1014719
4. Jensen, A. G., et al. (1999). Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Archives of Internal Medicine, 159, 1437–1444. https://doi.org/10.1001/archinte.159.13.1437
5. Smith, S., Rowbotham, N. J., & Regan, K. H. (2018). Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis (Review). Cochrane Database Systematic Review. https://doi.org/10.1002/14651858.CD001021.pub3
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献